中山醫學大學機構典藏 CSMUIR:Item 310902500/15737
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7421042      在线人数 : 264
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/15737


    题名: The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
    作者: SC, Su
    CW, Lin
    WE, Yang
    WL, Fan
    SF, Yang
    贡献者: 中山醫大口腔科學研究所
    关键词: Angiogenesis;extracellular matrix (ECM);integrin;malignancy;matrix metalloprotease (MMP);metastasis;urokinase plasminogen activator (uPA)
    日期: 2015-12-14
    上传时间: 2016-08-11T04:09:00Z (UTC)
    ISSN: 1472-8222
    摘要: INTRODUCTION:

    The urokinase plasminogen activator (uPA) system, comprising the serine protease uPA, its cognate receptor, uPAR, and two endogenous inhibitors, plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), is a key player in the break-down of extracellular matrix (ECM) and basement membrane. Elevated expression of uPA and uPAR is observed in numerous cancer types and associated with poor prognosis.

    AREAS COVERED:

    In addition to the aberrant expression during tumor development, the components of uPA system are functionally involved in various processes that are prerequisite for cancer progression. These processes include, but not limited to, ECM degradation, angiogenesis, cell proliferation, adhesion, migration and epithelial-mesenchymal transition. All of these findings implicate uPA system as a target for cancer treatment. Thus, therapeutic agents and approaches to targeting the constituents of uPA system, mainly at their expression level and biological activities, have been extensively used in antineoplastic investigations.

    EXPERT OPINION:

    Because of promising results obtained from previous preclinical studies, several clinical trials aimed at inhibiting the expression or function of uPA/uPAR have been completed or are ongoing. In these trials, favorable outcomes in reducing metastatic spread and extending the lifespan of cancer patients have been reported, and no severe adverse events were observed.
    URI: http://dx.doi.org/10.1517/14728222.2016.1113260
    https://ir.csmu.edu.tw:8080/ir/handle/310902500/15737
    關聯: Expert Opin Ther Targets. 2016 May;20(5):551-66.
    显示于类别:[牙醫學系暨碩士班] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML366检视/开启


    检视Licence

    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈